

1 **Optimal vaccine allocation for COVID-19 in the Netherlands: a data-driven** 2 **prioritization**

3

4 Fuminari Miura^{1,2}, Ka Yin Leung¹, Don Klinkenberg¹, Kylie E. C. Ainslie^{1,3,4}, Jacco Wallinga^{1,5}

5

6 ¹ Centre for Infectious Disease Control, National Institute for Public Health and the Environment
7 (RIVM), Bilthoven, the Netherlands

8 ² Center for Marine Environmental Studies (CMES), Ehime University, Ehime, Japan

9 ³ School of Public Health, Imperial College London, London, United Kingdom

10 ⁴ MRC Centre for Global Infectious Disease Analysis and Abdul Latif Jameel Institute for Disease
11 and Emergency Analytics, Imperial College London, London, United Kingdom

12 ⁵ Department of Biomedical Data Sciences, Leiden University Medical Center (LUMC), Leiden, the
13 Netherlands

14

15

16 *Corresponding author

17 Email: fuminari.miura@rivm.nl

18

19

20 **Author contributions**

21 Conceptualization: FM JW.

22 Data curation: FM.

23 Formal analysis: FM KL JW.

24 Investigation: FM.

25 Methodology: FM KL DK JW.

26 Software: FM.

27 Validation: FM KL JW.

28 Visualization: FM.

29 Writing – original draft: FM KL DK KA JW.

30 Writing – review & editing: FM KL DK KA JW.

31

32 **Data Availability**

33 All data are available from GitHub repository (https://github.com/fmiura/VacAllo_2021).

34

35 **Funding**

36 FM acknowledges funding from Japan Society for the Promotion of Science (JSPS KAKENHI,
37 Grant Number 20J00793). This project has received funding from the European Union's Horizon
38 2020 research and innovation programme - project EpiPose (grant agreement number 101003688).

39

40 **Competing interests**

41 The authors have declared that no competing interests exist.

42

43 **Acknowledgement**

44 We thank Jantien Backer for sharing the data on contact matrices in the Netherlands, and Scott
45 McDonald for helpful discussions.
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

46 **Abstract**

47 For the control of COVID-19, vaccination programmes provide a long-term solution. The
48 amount of available vaccines is often limited, and thus it is crucial to determine the allocation
49 strategy. While mathematical modelling approaches have been used to find an optimal
50 distribution of vaccines, there is an excessively large number of possible schemes to be simulated.

51 Here, we propose an algorithm to find a near-optimal allocation scheme given an
52 intervention objective such as minimization of new infections, hospitalizations, or deaths, where
53 multiple vaccines are available. The proposed principle for allocating vaccines is to target
54 subgroups with the largest reduction in the outcome of interest, such as new infections, due to
55 vaccination that fully immunizes a single individual. We express the expected impact of
56 vaccinating each subgroup in terms of the observed incidence of infection and force of infection.
57 The proposed approach is firstly evaluated with a simulated epidemic and then applied to the
58 epidemiological data on COVID-19 in the Netherlands.

59 Our results reveal how the optimal allocation depends on the objective of infection control.
60 In the case of COVID-19, if we wish to minimize deaths, the optimal allocation strategy is not
61 efficient for minimizing other outcomes, such as infections. In simulated epidemics, an allocation
62 strategy optimized for an outcome outperforms other strategies such as the allocation from young
63 to old, from old to young, and at random. Our simulations clarify that the current policy in the
64 Netherlands (i.e., allocation from old to young) was concordant with the allocation scheme that
65 minimizes deaths.

66 The proposed method provides an optimal allocation scheme, given routine surveillance
67 data that reflect ongoing transmissions. The principle of allocation is useful for providing plausible
68 simulation scenarios for complex models, which give a more robust basis to determine
69 intervention strategies.

70
71

72 **Author summary**

73 Vaccination is the key to controlling the ongoing COVID-19 pandemic. In the early stages of
74 an epidemic, there is shortage of vaccine stocks. Here, we propose an algorithm that computes an
75 optimal vaccine distribution among groups for each intervention objective (e.g., minimizing new
76 infections, hospitalizations, or deaths). Unlike existing approaches that use detailed information on
77 at-risk contacts between and among groups, the proposed algorithm requires only routine
78 surveillance data on the number of cases. This method is applicable even when multiple vaccines
79 are available. Simulation results show that the allocation scheme optimized by our algorithm
80 performed the best compared with other strategies such as allocating vaccines at random and in
81 the order of age. Our results also reveal that an allocation scheme optimized for one specific
82 objective is not necessarily efficient for another, indicating the importance of the decision-making
83 at the early phase of distributions.

84

85 Introduction

86 SARS-CoV-2 has posed a great threat to public health. As of 8 July 2021, 33,270,049 cases
87 and 740,809 deaths with COVID-19 have been reported in the EU/EEA (1), and globally there have
88 been 4,006,882 deaths reported (2). While non-pharmaceutical interventions (NPIs) reduce
89 transmission (3,4), the societal cost of implementing these measures is enormous (5,6), and the
90 effect is short-lived. Vaccination offers a long-term approach to control COVID-19.

91 Currently, sixteen vaccines have been approved for use, 99 companies are still conducting
92 clinical trials to develop next generation vaccines (7). There is a limited amount of vaccine
93 available, especially in low- and middle-income countries, because of narrow production capacity
94 and logistics (2,8,9). There is an urgent need to optimize the allocation of scarce vaccines.

95 The optimal allocation depends on the objective of infection control. If the objective is to
96 minimize hospitalizations, it might be best to target those with the highest risk of severe illness
97 upon infection. If the objective is to reduce transmission of infection, it might be best to target the
98 individuals who contribute most to future infections. Similar allocation problems were previously
99 explored for influenza vaccination programmes (10–12). The allocation of COVID-19 vaccines has
100 been evaluated in combination with NPIs (13–15), with age-varying vaccine efficacy (16), and with
101 different sizes of the vaccine stockpile (17,18). These studies examined plausible scenarios with
102 numerous combinations of models and parameters; however, the challenge here is that there are
103 innumerable possible allocation schemes to compare.

104 Here we show a data-driven approach to find optimal allocation schemes, by age group
105 and vaccine type, that minimize either new infections, hospitalizations, or deaths. As per previous
106 studies (13–18), we stratify the population by age, because age is shown to be an important risk
107 factor for susceptibility (19,20), severe illness (21,22), and mortality (21,23,24). We apply the
108 proposed approach to a simulated epidemic to evaluate its performance. We also test it with
109 epidemiological data of COVID-19 in the Netherlands, in order to find optimal allocation schemes
110 for different types of vaccines.
111

112 Results

113 *Impact of a single unit of vaccination*

114 We are interested in prioritizing a subgroup, to target vaccination of individuals in group i ,
115 by considering within- and between-subgroup transmissions. To find optimal allocation schemes,
116 the proposed approach relies on establishing the impact of a single unit of vaccine (i.e., the number
117 of doses to fully immunize a single individual), as described in the following three steps.

118 First, we write an age-stratified transmission process in matrix form by introducing the
119 next generation matrix \mathbf{K} (25–27). The next generation matrix \mathbf{K} gives the number of new infections
120 in a successive generation, such that the number of new infections at time $t + 1$ after one
121 generation of infections is $\mathbf{x}(t + 1) = \mathbf{K}\mathbf{x}(t)$. Note that \mathbf{K} is a $m \times m$ matrix, and we have m age
122 groups. We start with a $m \times 1$ vector of age-specific infection at time t , $\mathbf{x}(t)$.

123 Second, we define the “impact” of a single unit of vaccination as the reduction in the
124 number of new infections generated by an infected individual. A decrease in the number of
125 infected individuals at time $t + 1$, $\mathbf{x}(t + 1)$, is expressed as a result of changes in the next
126 generation matrix \mathbf{K} and in the number of infected individuals $\mathbf{x}(t)$ due to vaccinating one
127 individual. With simplified notation, we can write this as $\mathbf{x}'(t + 1) = \mathbf{K}'\mathbf{x}(t) + \mathbf{K}\mathbf{x}'(t)$, where \mathbf{K}'
128 and $\mathbf{x}'(t)$ are derivatives with respect to the number of vaccinated individuals; $\mathbf{K}'\mathbf{x}(t)$ is the direct
129 effect of vaccinating an individual and removing them from the susceptible population and $\mathbf{K}\mathbf{x}'(t)$
130 is the indirect effect of vaccinating a single individual by reducing onward infections (see Eq.S4
131 and Eq.S7 for full notation).

132 Third, the main interest here is to approximate the next generation matrix \mathbf{K} using
133 observed epidemiological data. By approximating \mathbf{K} , we can calculate above-defined changes
134 without knowing the detailed contact information between groups. To derive the approximated
135 form, we require that at-risk contacts are reciprocal. With this condition, the next generation
136 matrix \mathbf{K} can be safely approximated by the combination of the force of infection $\frac{x_i(t)}{s_i(t)}$ (i.e.,
137 incidence rate of new infections $x_i(t)$ per susceptible individual $s_i(t)$) and the incidence rate of
138 new infections per individual $\frac{x_i(t)}{n_i}$, and its approximation error is guaranteed to be small if the
139 observation interval for new infections is more than two generation intervals (28) (see detailed
140 derivation in **SI Text-1**).

141 Using the above results, when age group i is targeted for vaccination, its impact can be
142 measured as the contribution of the change in group i to the relative reduction in the number of
143 new infections after one generation of infection (see Eq. S11 in **SI Text-1**). As a result, we can
144 define this quantity as the “importance weight” of infection $y_i^{(I)}$, given by

$$145 \quad y_i^{(I)} = Rfg \left(q_i^{(S)} + q_i^{(T)} \right) \frac{c_i x_i(t)}{a_i s_i(t)} \frac{x_i(t)}{n_i} \quad (\text{Eq. 1})$$

146 where R is the reproduction number, f and g are normalizing constants, $q_i^{(S)}$ and $q_i^{(T)}$ are vaccine
147 efficacies for susceptibility and transmissibility in age group i , c_i is per contact probability of
148 transmitting infection for age group i , and a_i is per contact probability of acquiring infection for
149 age group i . We can interpret the quantity $y_i^{(I)}$ as the expected reduction in the number of new
150 infections generated by an infected individual after introducing a single unit of vaccine in group i ,
151 compared with the counterfactual situation where no vaccine is introduced.

152 The importance weight can be generalized for other disease outcomes. We find that the
153 generalized form of Eq.1 for other disease outcomes can be written as the product of the relative
154 change in the number of new infections $y_i^{(I)}$ and a disease progression rate (see the derivation in **SI**
155 **Text-1**). To illustrate its application, we introduce the importance weight of hospitalization $y_i^{(H)}$
156 and death $y_i^{(D)}$, which are defined as the relative reduction in the number of hospitalizations and

157 deaths;

158
$$y_i^{(H)} = \eta_i y_i^{(I)} \quad (\text{Eq. 2})$$

159 and

160
$$y_i^{(D)} = \mu_i y_i^{(I)} \quad (\text{Eq. 3})$$

161 where η_i is the infection hospitalization rate and μ_i is the infection mortality rate for age group i .

162

163 *Prioritization algorithm*

164 Given a limited stockpile of vaccines, we assess the expected impacts of a single vaccination
165 on the number of new infections, hospitalization, or deaths, with importance weights (i.e., $y_i^{(I)}$,
166 $y_i^{(H)}$ and $y_i^{(D)}$ shown in Eq.1-3). In the case that there are multiple types of vaccines, we can define
167 importance weights by vaccine type. To illustrate the algorithm proposed in this study, we use the
168 example of minimization of hospitalization, letting $y_i^{(H)(j)}$ denote the importance weight of
169 hospitalization (H) for vaccine type j in age group i . By comparing age and vaccine type specific
170 importance weights, the sequential allocation is performed as described below:

171 Step-1: Decide the objective of infection control (in this example, minimizing hospitalization (H))

172 Step-2: Calculate importance weights $y_i^{(H)(j)}$ per age-group i and vaccine type j

173 Step-3: Find a combination of age-group i and vaccine type j that has the largest importance
174 weight; this provides the selected age group and selected vaccine type.

175 Step-4: Allocate a single unit of the selected vaccine to the selected age-group

176 Step-5: Re-calculate importance weights by decreasing the weights in the targeted age-group, as
177 $y_i^{(H)(j)} + \frac{dy_i^{(H)(j)}}{du_i}$. Others remain the same.

178 Step-6: Repeat above until the end of vaccine stockpile.

179 Note that in step-5 all the importance weights of the age group i are updated. This is because the
180 allocation of one vaccine type depletes susceptible and infectious individuals in the targeted age
181 group, and thus it affects the expected impacts of other vaccines from next iterations (see detailed
182 derivation in **SI Text-1**). The pseudo code for this algorithm is provided in **Table-S2**.

183 There are four conditions that should be met; (i) the epidemic grows exponentially over the
184 time interval, (ii) at-risk contacts are reciprocal, (iii) the observation interval for new infections is
185 sufficiently long, and (iv) there is no major change in the age distribution of the risk of infection.
186 With these assumptions, we can reconstruct the (approximated) next generation matrix and
187 calculate the expected impact on each outcome due to vaccination, without detailed information
188 about contacts between groups (28).

189

190 *Test against simulated data*

191 We test the performance of the proposed algorithm using a simulated epidemic. **Figure-**
192 **1(A)** illustrates the generated epidemic curve where we set the basic reproduction number R_0 to 1.2
193 and the generation time as 5 days, based on the estimates of SARS-CoV-2 infections, following
194 previous modelling studies (13,16) (see **Method** for details of simulation settings). Although only
195 partial observations on the incidence and force of infection are used as inputs, the allocation
196 strategies yielded by our algorithm perform better than other strategies that we tested in most
197 cases (i.e., random allocation, allocation from young to old groups, allocation from old to young
198 groups, and no vaccination) (**Figure-1(D)-(F)**).

199

200 *Age distribution of allocated vaccines by prioritization scheme*

201 We apply the proposed approach to epidemiological data on COVID-19 in the Netherlands.
202 Higher efficacious vaccines are allocated first, and then lower efficacious vaccines are distributed
203 later on (**Figure 2** and **Figure S2**). **Figure 2** shows the detailed breakdown of allocated vaccines by
204 age group and vaccine type in each allocation scheme, and all the schemes start with the highest
205 efficacious vaccine (i.e., Pfizer vaccine). Since high vaccine efficacy results in larger impacts per
206 vaccination (**Eq-2**), it is natural to prioritize the allocation of higher efficacious vaccines.

207 Depending on the objective of infection control, the type of vaccines that each age group
208 receives would differ. If a specific age group is significantly contributing to the objective, it is
209 better to distribute higher efficacious vaccines to that group. For example, there is a large
210 contribution of age 21-30 for the number of infections (**Figure S1**), and thus higher efficacious
211 vaccines are distributed to that group if the objective is to minimize the number of infections (top
212 row in **Figure 2**). If we wish to minimize the number of hospitalizations or deaths, those vaccines
213 would be distributed to the elderly (second and third rows in **Figure 2**).

214 The optimal timing of switching from one age group to another also varies by objective.
215 When we set the objective as the minimization of the number of infections or hospitalizations, the
216 selected allocation orders for these two objectives suggest to distribute vaccines to several age-
217 groups in parallel (first and second rows in **Figure 2** and **Figure S3**). By contrast, when we set the
218 objective as the minimization of the number of deaths, the allocation scheme generally focused on
219 one age group, from old to young, and did not switch to the next age group until the vaccination of
220 the first age group (i.e., age 60+) is finished (third row in **Figure 2** and **Figure S3**). In terms of the
221 order and the switching timing, the selected allocation scheme that minimizes deaths is concordant
222 with the current allocation policy in the Netherlands (29).
223

224 *Different benefits between vaccine prioritization strategies*

225 Allocation schemes that are optimized for one objective may not be optimal with respect to
226 another, as illustrated by our simulations. If we choose to minimize the number of infections, that
227 allocation scheme is not efficient for the minimization of deaths (**Figure 3 (A)**). In contrast, if we
228 wish to minimize the number of hospitalizations or deaths (**Figure 3 (B)** and **(C)**), those strategies
229 are not efficient for minimizing infections. Especially, the difference in the expected reduction is
230 larger at the early phase of allocations; this is because mainly younger age groups are drivers of
231 transmission (**Figure S1 (A)**), while younger individuals are not in high-risk groups in terms of
232 hospitalization or death (**Figure S1 (F)** and **(G)**).

233 The proposed algorithm finds the best solution at each allocation step. This results in an
234 optimal solution for small stockpiles, but this local optimal solution is not necessarily optimal for
235 larger stockpiles (so called “greedy algorithm” (30)). To elucidate this property, we simulate an
236 alternative situation, before the approval of the Janssen vaccine, where the breakdown of the stock
237 is Pfizer (40%), AstraZeneca (40%), and Moderna (20%). **Figure S4** illustrates that the allocation
238 scheme to minimize infections results in nearly equal reduction of infections at the end of
239 allocations compared to the other two schemes, although it performed best at the beginning phase.
240
241

242 **Discussion**

243 The present study proposes a prioritization algorithm that can find an optimal allocation of
244 vaccines to different age groups, even with a limited amount of data. Our simulation results show
245 how optimal allocation differs depending on the objective. We apply the algorithm to available

246 Dutch epidemiological data on COVID-19, and the allocation scheme that minimizes deaths is
247 concordant with the current policy in the Netherlands that allocates vaccines from old to young
248 (29).

249 The proposed method provides first principles to find optimal allocation schemes with
250 limited data, and the output can also be used as a complementary tool to existing computational
251 approaches. Previous studies hinged on dynamic modeling to determine the prioritization of
252 vaccine allocation (13,16,17), and our algorithm can inform a near-optimal distribution of vaccines
253 as input values for those simulations. The proposed method can be used as a cross-check of
254 assumptions in dynamic models, because it does not require the detailed information on contact
255 matrices or non-pharmaceutical interventions. In the COVID-19 pandemic, we have already
256 observed immediate changes of the age distribution of reported cases (20,31), and contact patterns
257 during lockdown are different from usual patterns (32). The strength of our approach is that it
258 relies only on routine surveillance data.

259 Choosing a different objective for COVID-19 control implies choosing a different optimal
260 allocation scheme. In the case of SARS-CoV-2 infection, individuals who are at higher risk of
261 severe illness and who transmit are different (19,22). Our results (**Fig-1** and **Fig-3**) illustrated that,
262 if we weigh an objective (e.g., minimization of infections) and choose a strategy, the selected
263 scheme is not necessarily efficient for the other objectives (e.g., minimization of hospitalizations
264 and deaths). In our analysis, the difference in the reduction of each outcome was larger at the
265 earlier phase of vaccinations (**Fig-3**), indicating the importance of decision-making in the
266 beginning stage of allocations. While vaccine rollout has progressed rapidly in the first half of 2021
267 in high-income countries, there is large vaccine inequity globally (33). In many low- and middle-
268 income countries vaccine rollout is hindered by limited supply. An algorithm, such as the one
269 presented here, can be very useful to prioritize vaccine allocation in those countries where
270 maximum impact on disease outcomes must be achieved by a small supply of vaccines. Besides,
271 the proposed method can be easily generalized for a wider range of objectives, by multiplying a
272 disease progression rate (**SI Text-1**). The contribution of this study is to provide a solution how to
273 determine the subgroup with the largest contribution to different outcomes, given limited data.

274 When the proposed algorithm is applied, several assumptions and underlying conditions
275 of input values should be checked. First, confirmed case counts may not reflect the actual infection
276 dynamics in the population, depending on the level of ascertainment (34,35). Our approach relies
277 on the estimates of group-specific incidence and force of infection, as the best proxy of ongoing
278 transmission, and thus potential biases in the surveillance should be carefully scrutinized. Second,
279 our modelling simplified offering vaccine doses as a single event and parameterized vaccine
280 efficacies as the ability of reducing infections (Q_S) and blocking transmissions (Q_T), separately.
281 While there is an advantage to be able to evaluate various characteristics of vaccines by
282 incorporating both the marginal benefit and direct protection, additional supportive evidence on
283 the vaccine efficacy is required. Third, we assume that risk contacts are reciprocal and that
284 individuals are randomly mixing in each group. Although the reciprocity is not violated by a
285 broad class of diseases (32,36), if there were a specific age group that refuses vaccinations, and if its
286 proportion became significantly large, that kind of clustering effect might influence the result of
287 approximation of transmission processes.

288 In conclusion, the present study proposes an approach to find an optimal allocation of
289 vaccines for various objectives, given routine surveillance data. The principle of allocation is
290 simple and interpretable. These features are essential for decision making and for answering to
291 ethical questions that are inherent to allocation of scarce resources. In the context of COVID-19
292 control, the ability to base important decisions on real-time data, rather than the assumed effect of

293 contact patterns and non-pharmaceutical interventions, might provide a more robust scientific
294 basis for COVID-19 control.

295

296 References


- 297 1. ECDC. COVID-19 situation update for the EU/EEA, as of week 26. European Centre for Disease
298 Prevention and Control (ECDC). [cited 2021 Jul 9]. Available from: [https://www.ecdc.europa.eu/en/cases-](https://www.ecdc.europa.eu/en/cases-2019-ncov-eueea)
299 2019-ncov-eueea
- 300 2. WHO Coronavirus (COVID-19) Dashboard. [cited 2021 Jul 9]. Available from: <https://covid19.who.int/>
- 301 3. Kucharski AJ, Klepac P, Conlan AJK, Kissler SM, Tang ML, Fry H, et al. Effectiveness of isolation,
302 testing, contact tracing, and physical distancing on reducing transmission of SARS-CoV-2 in different
303 settings: a mathematical modelling study. *Lancet Infect Dis*. 2020 Oct;20(10):1151–60.
- 304 4. Ferretti L, Wymant C, Kendall M, Zhao L, Nurtay A, Abeler-Dörner L, et al. Quantifying SARS-CoV-2
305 transmission suggests epidemic control with digital contact tracing. *Science*. 2020 May 8;368(6491). Available
306 from: <http://dx.doi.org/10.1126/science.abb6936>
- 307 5. Sandmann FG, Davies NG, Vassall A, Edmunds WJ, Jit M, Centre for the Mathematical Modelling of
308 Infectious Diseases COVID-19 working group. The potential health and economic value of SARS-CoV-2
309 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis
310 and economic evaluation. *Lancet Infect Dis*. 2021 Mar 18; Available from: [http://dx.doi.org/10.1016/S1473-](http://dx.doi.org/10.1016/S1473-3099(21)00079-7)
311 3099(21)00079-7
- 312 6. Cutler DM, Summers LH. The COVID-19 Pandemic and the \$16 Trillion Virus. *JAMA*. 2020 Oct
313 20;324(15):1495–6.
- 314 7. Shrotri M, Swinnen T, Kampmann B, Parker EPK. An interactive website tracking COVID-19 vaccine
315 development. *Lancet Glob Health*. 2021 Mar 2; Available from: [http://dx.doi.org/10.1016/S2214-](http://dx.doi.org/10.1016/S2214-109X(21)00043-7)
316 109X(21)00043-7
- 317 8. Kluge H, McKee M. COVID-19 vaccines for the European region: an unprecedented challenge. *Lancet*.
318 2021 Mar 25; Available from: [http://dx.doi.org/10.1016/S0140-6736\(21\)00709-1](http://dx.doi.org/10.1016/S0140-6736(21)00709-1)
- 319 9. Cowling BJ, Lim WW, Cobey S. Fractionation of COVID-19 vaccine doses could extend limited supplies
320 and reduce mortality. *Nat Med*. 2021 Jul 5;1–2.
- 321 10. Mylius SD, Hagensars TJ, Luginer AK, Wallinga J. Optimal allocation of pandemic influenza vaccine
322 depends on age, risk and timing. *Vaccine*. 2008 Jul 4;26(29–30):3742–9.
- 323 11. Medlock J, Galvani AP. Optimizing influenza vaccine distribution. *Science*. 2009 Sep 25;325(5948):1705–
324 8.
- 325 12. Bansal S, Pourbohloul B, Meyers LA. A comparative analysis of influenza vaccination programs. *PLoS*
326 *Med*. 2006 Oct;3(10):e387.
- 327 13. Moore S, Hill EM, Tildesley MJ, Dyson L, Keeling MJ. Vaccination and non-pharmaceutical
328 interventions for COVID-19: a mathematical modelling study. *Lancet Infect Dis*. 2021 Mar 18; Available
329 from: <https://www.sciencedirect.com/science/article/pii/S1473309921001432>
- 330 14. Viana J, van Dorp CH, Nunes A, Gomes MC, van Boven M, Kretzschmar ME, et al. Controlling the
331 pandemic during the SARS-CoV-2 vaccination rollout: a modeling study. *medRxiv*. medRxiv; 2021.
332 Available from: <http://medrxiv.org/lookup/doi/10.1101/2021.03.24.21254188>
- 333 15. Giordano G, Colaneri M, Di Filippo A, Blanchini F, Bolzern P, De Nicolao G, et al. Modeling vaccination
334 rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy. *Nat Med*.
335 2021 Apr 16; Available from: <http://dx.doi.org/10.1038/s41591-021-01334-5>
- 336 16. Bubar KM, Reinholt K, Kissler SM, Lipsitch M, Cobey S, Grad YH, et al. Model-informed COVID-19
337 vaccine prioritization strategies by age and serostatus. *Science*. 2021 Jan 21 [cited 2021 Jan 22]; Available
338 from: <https://science.sciencemag.org/content/early/2021/01/21/science.abe6959>
- 339 17. Matrajt L, Eaton J, Leung T, Brown ER. Vaccine optimization for COVID-19: Who to vaccinate first?
340 *Science Advances*. 2020 Feb 1;7(6):eabf1374.
- 341 18. Buckner JH, Chowell G, Springborn MR. Dynamic prioritization of COVID-19 vaccines when social
342 distancing is limited for essential workers. *Proc Natl Acad Sci U S A*. 2021 Apr 20;118(16). Available from:
343 <http://dx.doi.org/10.1073/pnas.2025786118>
- 344 19. Davies NG, Klepac P, Liu Y, Prem K, Jit M, CMMID COVID-19 working group, et al. Age-dependent
345 effects in the transmission and control of COVID-19 epidemics. *Nat Med*. 2020 Aug;26(8):1205–11.
- 346 20. Zhang J, Litvinova M, Liang Y, Wang Y, Wang W, Zhao S, et al. Changes in contact patterns shape the
347 dynamics of the COVID-19 outbreak in China. *Science*. 2020 Jun 26;368(6498):1481–6.

- 348 21. Salje H, Tran Kiem C, Lefrancq N, Courtejoie N, Bosetti P, Paireau J, et al. Estimating the burden of
349 SARS-CoV-2 in France. *Science*. 2020 Jul 10;369(6500):208–11.
- 350 22. Walker PGT, Whittaker C, Watson OJ, Baguelin M, Winskill P, Hamlet A, et al. The impact of COVID-
351 19 and strategies for mitigation and suppression in low- and middle-income countries. *Science*. 2020 Jul
352 24;369(6502):413–22.
- 353 23. Levin AT, Hanage WP, Owusu-Boaitey N, Cochran KB, Walsh SP, Meyerowitz-Katz G. Assessing the
354 age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy
355 implications. *Eur J Epidemiol*. 2020 Dec 8; Available from: <http://dx.doi.org/10.1007/s10654-020-00698-1>
- 356 24. O’Driscoll M, Ribeiro Dos Santos G, Wang L, Cummings DAT, Azman AS, Paireau J, et al. Age-specific
357 mortality and immunity patterns of SARS-CoV-2. *Nature*. 2020 Nov 2; Available from:
358 <http://dx.doi.org/10.1038/s41586-020-2918-0>
- 359 25. Diekmann O, Heesterbeek JAP. *Mathematical Epidemiology of Infectious Diseases: Model Building,*
360 *Analysis and Interpretation*. John Wiley & Sons; 2000. 303 p.
- 361 26. Diekmann O, Heesterbeek JAP, Roberts MG. The construction of next-generation matrices for
362 compartmental epidemic models. *J R Soc Interface*. 2010 Jun 6;7(47):873–85.
- 363 27. van den Driessche P. Reproduction numbers of infectious disease models. *Infect Dis Model*. 2017
364 Aug;2(3):288–303.
- 365 28. Wallinga J, van Boven M, Lipsitch M. Optimizing infectious disease interventions during an emerging
366 epidemic. *Proc Natl Acad Sci U S A*. 2010 Jan 12;107(2):923–8.
- 367 29. Government of the Netherlands. Approach to corona vaccination in the Netherlands. 2021 [cited 2021
368 Jul 9]. Available from: [https://www.rijksoverheid.nl/onderwerpen/coronavirus-vaccinatie/aanpak-](https://www.rijksoverheid.nl/onderwerpen/coronavirus-vaccinatie/aanpak-coronavaccinatie/kinderen-en-jongeren)
369 [coronavaccinatie/kinderen-en-jongeren](https://www.rijksoverheid.nl/onderwerpen/coronavirus-vaccinatie/aanpak-coronavaccinatie/kinderen-en-jongeren)
- 370 30. Cormen TH, Leiserson CE, Rivest RL, Stein C. *Introduction To Algorithms*. MIT Press; 2001. 1180 p.
- 371 31. Feehan DM, Mahmud AS. Quantifying population contact patterns in the United States during the
372 COVID-19 pandemic. *Nat Commun*. 2021 Feb 9;12(1):1–9.
- 373 32. Backer JA, Mollema L, Vos ER, Klinkenberg D, van der Klis FR, de Melker HE, et al. Impact of physical
374 distancing measures against COVID-19 on contacts and mixing patterns: repeated cross-sectional surveys,
375 the Netherlands, 2016-17, April 2020 and June 2020. *Euro Surveill*. 2021 Feb;26(8). Available from:
376 <http://dx.doi.org/10.2807/1560-7917.ES.2021.26.8.2000994>
- 377 33. Roser M, Ritchie H, Ortiz-Ospina E, Hasell J. Coronavirus pandemic (COVID-19). *OurWorldInData.org*.
378 2021 [cited 2021 Jul 12]. Available from: <https://ourworldindata.org/coronavirus>
- 379 34. Russell TW, Golding N, Hellewell J, Abbott S, Wright L, Pearson CAB, et al. Reconstructing the early
380 global dynamics of under-ascertained COVID-19 cases and infections. *BMC Med*. 2020 Oct 22;18(1):332.
- 381 35. Omori R, Mizumoto K, Nishiura H. Ascertainment rate of novel coronavirus disease (COVID-19) in
382 Japan. *Int J Infect Dis*. 2020 Jul;96:673–5.
- 383 36. Wallinga J, Teunis P, Kretzschmar M. Using data on social contacts to estimate age-specific
384 transmission parameters for respiratory-spread infectious agents. *Am J Epidemiol*. 2006 Nov 15;164(10):936–
385 44.
- 386 37. Vos ERA, van Boven M, den Hartog G, Backer JA, Klinkenberg D, van Hagen CCE, et al. Associations
387 between measures of social distancing and SARS-CoV-2 seropositivity: a nationwide population-based study
388 in the Netherlands. *medRxiv*. medRxiv; 2021. Available from:
389 <http://medrxiv.org/lookup/doi/10.1101/2021.02.10.21251477>
- 390 38. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the
391 BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med*. 2020 Dec 10; Available from:
392 <https://doi.org/10.1056/NEJMoa2034577>
- 393 39. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-
394 1273 SARS-CoV-2 Vaccine. *N Engl J Med*. 2020 Dec 30; Available from:
395 <http://dx.doi.org/10.1056/NEJMoa2035389>
- 396 40. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the
397 ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised
398 controlled trials in Brazil, South Africa, and the UK. *Lancet*. 2021 Jan 9;397(10269):99–111.
- 399 41. Oliver SE, Gargano JW, Scobie H, Wallace M, Hadler SC, Leung J, et al. The Advisory Committee on
400 Immunization Practices’ Interim Recommendation for Use of Janssen COVID-19 Vaccine - United States,
401 February 2021. *MMWR Morb Mortal Wkly Rep*. 2021 Mar 5;70(9):329–32.

- 402 42. Caswell H. Sensitivity Analysis: Matrix Methods in Demography and Ecology. Springer, Cham; 2019.
- 403 43. Blower SM, Dowlatabadi H. Sensitivity and Uncertainty Analysis of Complex Models of Disease
- 404 Transmission: An HIV Model, as an Example. *Int Stat Rev.* 1994;62(2):229–43.
- 405 44. Inaba H. Age-Structured Population Dynamics in Demography and Epidemiology. Springer; 2017. 555
- 406 p.
- 407 45. Magnus JR, Neudecker H. Matrix Differential Calculus with Applications in Statistics and
- 408 Econometrics. Wiley; 1988. 393 p.
- 409 46. Caswell H. Matrix population models. Vol. 1. Sinauer Sunderland, MA, USA; 2000.
- 410 47. Golub GH, Van Loan CF. Matrix computations (3rd ed.). USA: Johns Hopkins University Press; 1996.
- 411

412 **Figures and Tables**

413



414

415

416

417

418

419

420

421

422


423

424

425

426

Fig-1. Simulated epidemic and evaluation of the impact of vaccination by allocation strategy. The epidemic is simulated by an age-structured SIR model. R_0 and generation time were set as 1.2 and 5 days, respectively. The population was stratified by 10-year age bin, and a contact matrix of the Netherlands in June 2020 was used for the simulation (32). Panel (A) illustrates the total incidence of infection in the population, and age-specific incidences (B) and the force of infection (C) reflect heterogeneous contacts between age-groups. The impact of vaccination on the number of infections (D), hospitalizations (E), and deaths (F) was compared under five different strategies; no vaccination (red), allocation from old to young groups (yellow), young to old groups (purple), at random (blue), and optimized allocation (green). For simplicity, the vaccination coverage was set as 40%, and the effect of vaccines was in place at day 50 (from the initial time point of the simulation), resulting in the immediate depletion of susceptible and infected individuals on that day.



427

428


429

430

431

432

Fig-2. The order of vaccine allocation by age and by prioritization strategy for a stockpile that suffices to vaccinate 80% of the population. From the top row, the objective is the minimization of infections, hospitalizations, and deaths respectively. From the left column, the proportion of vaccinated among age <20, 21-30, 31-40, 41-50, 51-60, 60+ are plotted over allocated vaccines. Note that the X-axis shows the percentage of allocated vaccines.



433

434

435

436

437

438

439

440

441

Fig-3. Performance of allocation schemes on different objectives for a stockpile that suffices to vaccinate 80% of the population. The Y-axis shows the percentage reduction in the number of infections (A), hospitalizations (B), and deaths (C), and the X-axis is the percentage of allocated vaccines. Red, light blue, and dark blue plots indicate the allocation strategies to minimize the number of infections, hospitalizations, and deaths respectively. The starting point of effective reproduction number (i.e., the reference point without any vaccination) was set as 1.2.

442 **Materials and Methods**

443 *Covid-19 epidemic data in the Netherlands*

444 The population data was stratified into six age groups [<20 , 21-30, 31-40, 41-50, 51-60, 60+].
445 For each age group, we used data on the population size, seroprevalence, incidence of notified
446 cases, maximum vaccine uptake (i.e., willingness to be vaccinated), COVID-19 hospitalization rate,
447 COVID-19 mortality rate, and vaccine efficacy against infection and transmission (**Figure S1**). The
448 seroprevalence data was obtained from the Pienter-Corona study among a representative sample
449 of the Dutch population, collected in June 2020 (37). We used this data to calculate the proportion
450 of susceptible individuals per group, that is, $1 - \text{seropositive rate}$. We used infection
451 hospitalization rate and infection mortality rate that were estimated by published studies based on
452 pooled analyses over 45 countries (22,24) rather than specific estimates for the Netherlands.

453 The maximum vaccine uptake was assumed to be 80% for all age groups. The vaccine
454 efficacy was assumed constant over age-groups (38–41). We assumed the same vaccine efficacies
455 against infection and transmission (**Figure-S1**). To calculate the expected decrease in the number of
456 new infections, hospitalizations, and deaths, as a function of the number of allocated vaccines, the
457 starting point of effective reproduction number R (i.e., the reference point without any vaccination)
458 was set to 1.2.

459 We allocated a vaccine stockpile that covers 80% of the total population. The breakdown of
460 the stock is Pfizer (46%), AstraZeneca (22%), Moderna (8%), and Janssen (24%). Note that we
461 considered the unit of vaccines as a set of full doses; for example, the Pfizer vaccine needs to be
462 administered twice, and the set of those two doses was defined as a single unit here. We assumed
463 that one person can receive only one type of vaccines. Thus, 80% of the population was vaccinated
464 when all vaccines were allocated.

465 *Performance evaluation with simulated epidemics*

467 We simulated an epidemic, using a deterministic SIR model, where all parameters were
468 known a priori. We evaluated five different allocation strategies: optimal allocation for each
469 objective (i.e., minimization of infections, hospitalizations, and deaths) determined by the
470 proposed algorithm; random allocation; allocation from young to old groups; allocation from old
471 to young groups; and no vaccination. To quantify the impact of vaccinations in each strategy, we
472 took the “no vaccination” scenario as a natural reference point. The population was stratified by 10
473 year age group, since a contact matrix of the Netherlands in June 2020 was available with those age
474 bins and used for the simulation (32). An age-structured SIR model was used to generate an
475 epidemic curve where R_0 was set as 1.2 with the fixed generation time as 5 days, based on the
476 estimates of SARS-CoV-2 infections following previous modelling studies (13,16). For simplicity,
477 per contact probability of acquiring infection (a_i) and per contact of transmitting infection (c_i) were
478 assumed to be equal, and the vaccine efficacy was 0.946 based on the estimate for Pfizer (38). The
479 available vaccine stock was set as 40% coverage of the population, which covers a half of the
480 population that are willing to get vaccinated.

481 As a practical application, observable information (i.e., the incidence of infection and the
482 force of infection) until day 45 was used as inputs, where day 0 is the initial time point of a
483 simulated SIR epidemic. The optimal distribution of vaccines to each age group was yielded by the
484 proposed algorithm. Note that the algorithm does not use the contact matrix. In each scenario, the
485 effect of allocated vaccines became in place at day 50 all at once, resulting in the immediate
486 depletion of susceptible and infected individuals in the population. Replication code is available
487 on GitHub (<https://github.com/fmiura/VacAllo> 2021).

488

489 *Derivation of importance weights*

490 For a broad class of compartmental models, the disease transmission is described as
491 transitions from discrete states (e.g., susceptible-infectious-recovered states in the SIR model), and
492 the dynamics is generated by a system of nonlinear ordinary differential equations (ODEs) that
493 depicts the change over time. By linearizing ODEs, any (linear) system can be described by a
494 matrix form (26). Within this linearized subsystem, one can determine the reproduction number R
495 as the dominant eigenvalue of the next generation matrix \mathbf{K} (25–27).

496 The first step is to relate the observed data to the next generation matrix \mathbf{K} . If at-risk
497 contacts are reciprocal, the next generation matrix \mathbf{K} becomes a product of symmetric matrices and
498 diagonalizable. This condition allows the decomposition of \mathbf{K} , and thus we can approximate \mathbf{K} by
499 the top left and right eigenvectors that can be (approximately) described by the incidence of new
500 infections and force of infection (28).

501 Once the matrices are specified, we can evaluate the impact of a single unit of vaccination,
502 as the sensitivity (or elasticity) of the transition matrix (see the general idea of the sensitivity of a
503 matrix in (42), and its application in infectious disease epidemiology in (27,43)). The change in the
504 number of infections per single vaccination can be formulated as the result of depletion of
505 susceptible and infectious individuals from the population (**Eq-S4 in Text-S1**), and subsequently,
506 we obtain its effect on the dominant eigenvalue of the next generation matrix that was already
507 introduced in the first step as an approximation with observed data. The expected impact here is
508 defined as the importance weight; if we allocate a single unit of vaccine to the group with the
509 largest importance weight, that results in the minimization of the dominant eigenvalue, that is, the
510 expected number of infections, hospitalizations, or deaths in total.

511

512 **Supporting information**

513 **Figure S1.** Age-specific input data

514 **Figure S2.** Simulated vaccine allocations by age and by vaccine type

515 **Figure S3.** Simulated prioritization of age-group by allocation scheme

516 **Figure S4.** Simulated impact of vaccinations

517


518 **Table S1.** Notation and meaning of variables

519 **Table S2.** Pseudo code of the allocation algorithm

520

521 **Text S1.** Mathematical details

522



523

524 **Figure S1.** Age-specific input data for the proposed algorithm to obtain optimal allocation

525 schemes. (A) Population structure in the Netherlands in 2019 (B) Seroprevalence observed in the

526 Pienter-Corona study among a representative sample of the Dutch population in June (37). (C)

527 Incidence of notified cases, in 30 days before October 19, 2020 (D) Vaccine Efficacy by vaccine type.


528 From lighter to darker blue, bars indicate Pfizer Moderna, Janssen, AstraZeneca. Note that the

529 constant efficacy by age here is an assumption, based on reported over all vaccine efficacies (38–

530 41). (E) Maximum vaccine uptake per age group. 80% for all groups is assumed here. (F) COVID-


531 19 hospitalization rate. These values are based on (22). (G) COVID-19 mortality rate. These values

532 are based on (24).




533
534
535
536
537
538
539

Figure S2. Vaccine allocations based on simulated data when the objective is to minimize the number of infections ((A) and (B)), hospitalizations ((C) and (D)), and deaths ((E) and (F)). In left three panels, from lighter to darker blue, bars indicate Pfizer Moderna, Janssen, AstraZeneca. In right three panels, the darker color shows the older age groups, and age bins are [20<,21-30,31-40,41-50,51-60,60+].



540
541
542
543
544

Figure S3. Vaccine allocation based on simulated data when the objective is to minimize the number of infections (A), hospitalizations (B), and deaths (C). The darker color shows the older age groups, and age bins are [20<,21-30,31-40,41-50,51-60,60+].



545
546 **Figure S4.** Performance of allocation schemes on different objectives for a stockpile that suffices to
547 vaccinate 80% of the population. The breakdown of the stock is Pfizer (40%), AstraZeneca (40%),
548 and Moderna (20%). The Y-axis shows the percentage reduction in the number of infections (A),
549 hospitalizations (B), and deaths (C), and the X-axis is the percentage of allocated vaccines. Red,
550 light blue, and dark blue plots indicate the allocation strategies to minimize the number of
551 infections, hospitalizations, and deaths respectively. The starting point of effective reproduction
552 number (i.e., the reference point without any vaccination) was set as 1.2.

553

554

555 **Table S1.** Notation and meaning of variables

Symbol	Meaning
K	Next generation matrix with elements k_{ij}
S	Matrix with group-specific number of susceptible individuals $s_i(t)$ in group i at time t
A	Matrix with per contact probability of acquiring infection a_i for group i
B	Matrix with group-specific contact parameter b_{ij} (i.e., the proportion of group i contacted by an infective in group j)
C	Matrix with per contact probability of transmitting infection c_i for group i
N	Matrix with the population size n_i of group i
D	Matrix with group-specific infection mortality rate μ_i on the diagonal
H	Matrix with group-specific infection hospitalization rate η_i on the diagonal
U	Matrix with the number of vaccinations u_i given to group i on the diagonal
$P^{(l)}$	Projection matrix that describes expected reductions in new infections in group i with the dominant eigenvalue $\lambda_1^{(l)}$
Q_s	Matrix with vaccine efficacy against acquiring infection $q_i^{(s)}$ on the diagonal
Q_T	Matrix with vaccine efficacy against transmission $q_i^{(T)}$ on the diagonal
u	Vector with the number of vaccinated individuals u_i in group i
$x(t)$	Vector with group-specific number of new infections $x_i(t)$ in group i at time t
$h(t)$	Vector with group-specific number of new infections $h_i(t)$ in group i at time t
f, g	Normalization constants
R	Reproduction number (top eigenvalue of the next generation matrix K)
τ	Generation interval of infections
$z^{(j)}$	Number of available vaccine stocks for type j

556

557

558 **Table S2.** Pseudo code of the allocation algorithm

Algorithm 1

Input variables:

- Number of available vaccine stocks $z^{(j)}$ for each vaccine type j
- Group-specific probability of acquiring infection per contact a_i and of transmitting infection per contact c_i
- Group-specific population size n_i
- Group-specific number of new infections $x_i(t)$ in group i at time t
- Group-specific number of susceptible individuals $s_i(t)$ in group i at time t
- Group- and vaccine type-specific vaccine efficacy against acquiring infection $q_i^{(S)(j)}$
- Group- and vaccine type-specific vaccine efficacy against transmission $q_i^{(T)(j)}$
- Initial value of the effective reproduction number R

Pseudo code:

- Define the objective of infection control (e.g., the number of hospitalizations)
- Calculate initial importance weights $y_i^{(H)(j)}$ per age group i per vaccine type j
- Set the number of allocated vaccine type j for age group i as 0: $u_i^{(j)} \leftarrow 0$
- Run loops below until (i) all $z^{(j)}$ becomes zero OR (ii) all group reach the maximum uptake:

For $j = 1, 2, \dots, J$ **do:**

For $i = 1, 2, \dots, I$ **do:**

Find the largest importance weight $y_{i^*}^{(H)(j^*)}$

If $y_{i^*}^{(H)(j^*)} = y_i^{(H)(j)}$ **then:**

Allocate a single unit of vaccine type j to the selected group i : $u_i^{(j)} \leftarrow u_i^{(j)} + 1$; $z^{(j)} \leftarrow z^{(j)} - 1$

Update all importance weights of the selected group i : $y_i^{(H)(j)} \leftarrow y_i^{(H)(j)} + \frac{dy_{i^*}^{(H)(j^*)}}{du}$

Else:

Keep the importance weights in the unselected group i : $y_i^{(H)(j)} \leftarrow y_i^{(H)(j)}$

If $z^{(j)} = 0$ **then:**

Update all importance weights of the vaccine type j that is out of stock: $y_i^{(H)(j)} \leftarrow 0$

If $\sum_j u_i^{(j)} = (\text{maximum vaccine uptake of group } i)$ **then:**

Update all importance weights of the selected group i that reaches the max uptake: $y_i^{(H)(j)} \leftarrow 0$

End

End

Output variables:

- The number of allocated vaccine type j for age group i as a function of iteration l : $u_i^{(j)}(l)$
- Importance weights per age group i per vaccine type j as a function of iteration l : $y_i^{(H)(j)}(l)$

559

560

561 **Text S1. Mathematical details**

562

563 *1. Mathematical details*

564 *1.1 Objective*

565 The aim of following calculations is to formulate the expected impact of targeted
566 vaccinations. We firstly present our approach to relate the expected changes in the next generation
567 matrix \mathbf{K} to the observed epidemiological data (i.e., the number of new infections per group). We
568 then generalize the argument to quantify the expected impact in the number of hospitalizations
569 and deaths.

570 The following analysis is known as “perturbation analysis” of a matrix in demography and
571 population ecology (42,44), and we will refer to theorems and proofs introduced by those exiting
572 literatures. For consistent notations, we follow Magnus and Neudecker (1988) (45); matrices are
573 denoted by upper case bold symbols (e.g., \mathbf{A}), and vectors are denoted by lower case bold symbols
574 (\mathbf{n}). Note that we define the derivatives of a matrix (or vector) as the matrix (or vector) of
575 derivatives of the elements (e.g., $\frac{dY}{dX} = \left(\frac{dy_{ij}}{dx_{ij}}\right)$ and $\frac{dy}{dx} = \left(\frac{dy_i}{dx_i}\right)$). All notations and definitions of
576 variables are shown in **Table-S2**.

577

578 *1.2 Next generation matrix*

579 The host population is subdivided into m groups. The next generation matrix \mathbf{K} gives the
580 number of new infections in a successive generation, such that the number of new infections at
581 time $t + 1$ after 1 generations of infections is $\mathbf{x}(t + 1) = \mathbf{K}\mathbf{x}(t)$. For a large class of transmission
582 models such as susceptible-infected-recovered model (SIR) model, the next generation matrix \mathbf{K}
583 can be written as

584

$$\mathbf{K} = \mathbf{S}\mathbf{A}\mathbf{B}\mathbf{C}$$

585 where matrices \mathbf{S} , \mathbf{A} , \mathbf{B} , and \mathbf{C} have the following epidemiological interpretation: \mathbf{S} is a matrix with
586 group-specific number of susceptible individuals $s_i(t)$ on the diagonal, \mathbf{A} is a matrix with per
587 contact probability of acquiring infection a_i on the diagonal, \mathbf{B} is a contact matrix with elements
588 b_{ij} , and \mathbf{C} is a matrix with group-specific per contact probability of transmitting infection c_i on the
589 diagonal. Note that only \mathbf{S} is time-dependent (and thus \mathbf{K} is also time-dependent). For readability,
590 when it is obvious from the context, we do not write the dependency on time. We require that at-
591 risk contacts are reciprocal, and thus the matrix \mathbf{B} is assumed to be symmetric. Thus, the next
592 generation matrix \mathbf{K} becomes a product of symmetric matrices and diagonalizable.

593

594 *1.3 Approximation by observed infections*

595 By diagonalizing the next generation matrix \mathbf{K} , we have

596

$$\mathbf{K} = \mathbf{W}\mathbf{\Lambda}\mathbf{W}^{-1}$$

597 where $\mathbf{\Lambda}$ is a diagonal matrix that has eigenvalues $R, \lambda_2, \lambda_2, \dots, \lambda_m$ as its elements and zeros
598 elsewhere, where R is the dominant eigenvalue and is often referred to as the reproduction
599 number. The matrix \mathbf{W} has as columns the right eigenvectors $\mathbf{w}_1, \mathbf{w}_2, \dots, \mathbf{w}_m$. The matrix \mathbf{W}^{-1} is the
600 inverse of the matrix \mathbf{W} that has the left eigenvectors $\mathbf{v}_1, \mathbf{v}_2, \dots, \mathbf{v}_m$ as its rows. We require that an
601 infector introduced in an arbitrary group reproduces a finite number of new infections in every
602 group, and this condition ensures that the next generation matrix \mathbf{K} is primitive. In such condition,
603 the Perron-Frobenius Theorem guarantees that R, \mathbf{w}_1 , and \mathbf{v}_1 are real and non-negative (25,42).

604 After τ generations of infections, the number of new infections at time $t + \tau$ is given by $\mathbf{x}(t +$
605 $\tau) = \mathbf{K}^\tau \mathbf{x}(t) = \mathbf{W}\mathbf{\Lambda}^\tau \mathbf{W}^{-1} \mathbf{x}(t)$. By using both right and left eigenvectors, we can rewrite the formula
606 as

607

$$\mathbf{x}(t + \tau) = \sum_i \lambda_i^\tau \mathbf{w}_i \mathbf{v}_i^T \mathbf{x}(t).$$

608 Note that $\mathbf{x}(t)$ is a vector that has the number of new infections in age group i as its elements,
 609 denoted as $x_i(t)$ and that the dominant eigenvalue λ_1 is the reproduction number R . If the
 610 dominant eigenvalue is strictly greater than other eigenvalues, the first term $R\mathbf{w}_1\mathbf{v}_1^T$ will eventually
 611 dominate other terms, and other all the terms will become negligible. This characteristic yields the
 612 approximated next generation matrix

$$613 \quad \bar{\mathbf{K}} = R\mathbf{w}_1\mathbf{v}_1^T. \quad (\text{Eq. S1})$$

614 Now it is of interest to approximate the top right and left eigenvectors, \mathbf{w}_1 and \mathbf{v}_1 , by
 615 observations. If the observation interval is long enough (typically longer than two generations of
 616 infections), we can safely approximate the top right eigenvector \mathbf{w}_1 with the number of new
 617 infections $\mathbf{x}(t)$ (28). Thus, we have

$$618 \quad \mathbf{w}_1 \approx f\mathbf{x}(t) \quad (\text{Eq. S2})$$

619 where f is the normalizing constant given by $f = \frac{1}{\sum_i x_i(t)}$. This result is also known as the strong
 620 ergodic theorem (see ref (46), p.86). Since the contact matrix \mathbf{B} is symmetric and thus the next
 621 generation matrix \mathbf{K} is a product of symmetric matrices, there exists a transformation matrix \mathbf{M}
 622 that transposes \mathbf{K} , such that $\mathbf{MKM}^{-1} = \mathbf{K}^T$. With this relationship, we can project the top left
 623 eigenvector \mathbf{v}_1 along the top right eigenvector \mathbf{w}_1 , and subsequently

$$624 \quad \mathbf{v}_1 \approx \frac{g}{f}\mathbf{CA}^{-1}\mathbf{S}^{-1}\mathbf{w}_1 \approx g\mathbf{CA}^{-1}\mathbf{S}^{-1}\mathbf{x}(t). \quad (\text{Eq. S3})$$

625 where g is the normalization constant given by $g = \frac{\sum_i x_i(t)}{\sum_i \frac{c_i x_i(t)}{a_i s_i(t)}}$. See detailed derivation in the section

626 3.4. of supporting info in (28).

627
 628 *1.4 Sensitivity of the number of new infections to targeted vaccinations*

629 *1.4.1 Changes in the number of new infections due to vaccinations*

630 A decrease in $\mathbf{x}(t + 1)$ is expressed as a result of changes in the next generation matrix \mathbf{K}
 631 and in the number of infected individuals $\mathbf{x}(t)$:

$$632 \quad \frac{d\mathbf{x}(t + 1)}{du} = \frac{d\mathbf{K}}{dU}\mathbf{x}(t) + \mathbf{K}\frac{d\mathbf{x}(t)}{du} \quad (\text{Eq. S4})$$

633 where $\frac{d\mathbf{K}}{dU}\mathbf{x}(t)$ is the direct effect of vaccinating an individual and removing them from the
 634 susceptible population and $\mathbf{K}\frac{d\mathbf{x}(t)}{du}$ is the indirect effect of vaccinating a single individual by
 635 reducing onward infections.

636
 637 *1.4.2 Perturbation in the next generation matrix \mathbf{K}*

638 We focus on the impact of vaccinations when vaccines are allocated to the group that can
 639 be immune or susceptible. The perturbation of next generation matrix $\frac{d\mathbf{K}}{dU}$ is expressed in terms of
 640 the change in the number of susceptible individuals $\frac{dS}{dU}$ due to vaccinations, such that $\frac{d\mathbf{K}}{dU} =$
 641 $\left(\frac{dS}{dU}\right)(\mathbf{ABC})$. We denote the vaccine efficacy on susceptibility as \mathbf{Q}_S , and the depletion of susceptible
 642 individual is written as

$$643 \quad \frac{dS}{dU} = -\mathbf{Q}_S\mathbf{SN}^{-1}$$

644 where \mathbf{N} is a diagonal matrix that has elements of total population in each age group n_i . Since $\frac{d\mathbf{K}}{dU} =$
 645 $\left(\frac{dS}{dU}\right)(\mathbf{ABC}) = \left(\frac{dS}{dU}\right)(\mathbf{S}^{-1}\mathbf{K})$, the perturbation of the next generation matrix is

$$646 \quad \frac{d\mathbf{K}}{dU} = (-\mathbf{Q}_S\mathbf{SN}^{-1})(\mathbf{S}^{-1}\mathbf{K})$$

647 and thus

$$648 \quad \frac{d\mathbf{K}}{dU} = -\mathbf{Q}_S\mathbf{N}^{-1}\mathbf{K} \quad (\text{Eq. S5})$$

649 because \mathbf{S} and \mathbf{N} are diagonal matrices and thus commutative. The derivation is same as that of
 650 section 3.5. of supporting info in (28). Note that the vaccine efficacy of susceptibility here (i.e., \mathbf{Q}_S)
 651 is defined as the probability of protecting infection per infectious contact (see next section 1.4.3 for
 652 another effect of vaccinations, which considers the prevention of transmission from an infectious
 653 individual).

654

655 1.4.3 Perturbation in the number of infected individuals $\mathbf{x}(t)$

656 If vaccines are allocated also to infected individuals $\mathbf{x}(t)$ at time t , the change in the
 657 number of infected (infectious) individuals is

$$658 \frac{d\mathbf{x}(t)}{du} = -\mathbf{Q}_T \mathbf{N}^{-1} \mathbf{x}(t). \quad (\text{Eq. S6})$$

659 where \mathbf{Q}_T is the vaccine efficacy against the transmissibility.

660

661 1.4.4 Importance weight of infection

662 By substituting Eq.S5 and Eq.S6 to Eq.S4, the decrease in the number of new infections after
 663 one generation is rewritten as

$$664 \frac{d\mathbf{x}(t+1)}{du} = \underbrace{-\mathbf{Q}_S \mathbf{N}^{-1} \mathbf{K} \mathbf{x}(t)}_{\text{direct effect}} - \underbrace{\mathbf{K} \mathbf{Q}_T \mathbf{N}^{-1} \mathbf{x}(t)}_{\text{indirect effect}}. \quad (\text{Eq. S7})$$

665 The interpretation of first term is the reduction in the number of new infections because
 666 susceptible individuals were depleted (i.e., direct effect), and that of second term is the effect
 667 preventing onward infections because infectious individuals are depleted (i.e., indirect effect).

668 Now we can relate this sensitivity $\frac{d\mathbf{x}(t+1)}{du}$ to observations. By approximating the next
 669 generation matrix by dominant right and left eigenvectors (i.e., $\bar{\mathbf{K}} = \mathbf{R} \mathbf{w}_1 \mathbf{v}_1^T$), the above equation is
 670 rewritten as

$$671 \frac{d\mathbf{x}(t+1)}{du} \approx -\mathbf{Q}_S \mathbf{N}^{-1} \bar{\mathbf{K}} \mathbf{x}(t) - \bar{\mathbf{K}} \mathbf{Q}_T \mathbf{N}^{-1} \mathbf{x}(t) = -(\mathbf{Q}_S \mathbf{N}^{-1} \mathbf{R} \mathbf{w}_1 \mathbf{v}_1^T + \mathbf{R} \mathbf{w}_1 \mathbf{v}_1^T \mathbf{Q}_T \mathbf{N}^{-1}) \mathbf{x}(t). \quad (\text{Eq. S8})$$

672 We set a projection matrix as $\mathbf{P}^{(l)} = \mathbf{Q}_S \mathbf{N}^{-1} \mathbf{R} \mathbf{w}_1 \mathbf{v}_1^T + \mathbf{R} \mathbf{w}_1 \mathbf{v}_1^T \mathbf{Q}_T \mathbf{N}^{-1}$ and its dominant eigenvalue as
 673 $\lambda_1^{(R)}$. When the vaccination is targeted to the group i , using Eq.S2 and S3, we obtain

$$674 \mathbf{R} \mathbf{w}_{1i} \mathbf{v}_{i1} \approx \mathbf{R} f g \frac{c_i x_i(t)^2}{a_i s_i(t)}. \quad (\text{Eq. S9})$$

675 We use the same approximation method as section 1.3 for the projection matrix $\mathbf{P}^{(l)}$ and its top
 676 right eigenvector $\mathbf{w}_1^{(l)}$. Given the sufficient length of observation intervals, we can safely
 677 approximate $\mathbf{w}_1^{(l)}$ by the number of new infections $\mathbf{x}(t)$ such that $\mathbf{w}_1^{(l)} \approx f \mathbf{x}(t)$ (see ref (46), p.86).
 678 Since $\mathbf{P}^{(l)} \mathbf{w}_1^{(l)} = \lambda_1^{(l)} \mathbf{w}_1^{(l)}$, the contribution of age group i to the dominant eigenvalue $\lambda_1^{(l)}$ is:

$$679 \lambda_1^{(l)} w_{i1}^{(l)} = \mathbf{P}_i^{(l)} w_{i1}^{(l)} \approx \left(\mathbf{R} f g \left(q_i^{(S)} + q_i^{(T)} \right) \frac{c_i x_i(t) x_i(t)}{a_i s_i(t) n_i} \right) w_{i1}^{(l)}. \quad (\text{Eq. S10})$$

680 We can interpret the quantity $\mathbf{R} f g \left(q_i^{(S)} + q_i^{(T)} \right) \frac{c_i x_i(t) x_i(t)}{a_i s_i(t) n_i}$ as the expected reduction in the number
 681 of new infections generated by a typical infected individual in group i after introducing a single
 682 unit of vaccine. Thus, we define this expected impact of a single vaccination in group i on the
 683 dominant eigenvalue $\lambda_1^{(l)}$ as the importance weight of infection:

$$684 y_i^{(l)} = \mathbf{R} f g \left(q_i^{(S)} + q_i^{(T)} \right) \frac{c_i x_i(t) x_i(t)}{a_i s_i(t) n_i} \quad (\text{Eq. S11})$$

685

686 1.5 Sensitivity of the number of hospitalizations to targeted vaccinations

687 1.5.1 Changes in the number of hospitalizations due to vaccinations

688 The number of hospitalized individuals $\mathbf{h}(t)$ at time t (i.e., $m \times 1$ vector with elements h_1 ,
 689 h_2, \dots, h_m) is defined as

$$690 \mathbf{h}(t) = \mathbf{H} \mathbf{x}(t)$$

691 where \mathbf{H} is a diagonal matrix with group-specific hospitalization rate $\eta_1, \eta_2, \dots, \eta_m$. Suppose that
 692 we wish to predict the number of hospitalizations after one generation of infections. We can write
 693 the number of new hospitalizations as

$$694 \quad \mathbf{h}(t + 1) = \mathbf{H}\mathbf{x}(t + 1) = \mathbf{H}\mathbf{K}\mathbf{x}(t).$$

695 Over the observation interval from t to $t + 1$, we assume the group-specific probability of
 696 hospitalization is constant.

697 Here we look at the perturbation of the expected number of hospitalizations $\mathbf{h}(t + 1)$ due to
 698 vaccinations. Since the infection hospitalization rate matrix \mathbf{H} is constant, the perturbation in $\mathbf{x}(t +$
 699 $1)$ is of interest. Therefore, using Eq.S4, the decrease in the number of hospitalizations can be
 700 written as

$$701 \quad \frac{d\mathbf{h}(t + 1)}{du} = \frac{d\mathbf{H}\mathbf{x}(t + 1)}{du} = \mathbf{H} \left(\frac{d\mathbf{K}}{dU} \mathbf{x}(t) + \mathbf{K} \frac{d\mathbf{x}(t)}{du} \right). \quad (\text{Eq.S12})$$

702 1.5.2 Importance weight of hospitalization

703 Using Eq.S12 and the result of section 1.4.4 such as Eq.S8, the small change in the expected
 704 number of hospitalizations after one generation is now written as

$$705 \quad \frac{d\mathbf{h}(t + 1)}{du} = \frac{d\mathbf{H}\mathbf{x}(t + 1)}{du} = -\mathbf{H}(\mathbf{Q}_S \mathbf{N}^{-1} \mathbf{R} \mathbf{w}_1 \mathbf{v}_1^T + \mathbf{R} \mathbf{w}_1 \mathbf{v}_1^T \mathbf{Q}_T \mathbf{N}^{-1}) \mathbf{x}(t).$$

706 Again, we set a projection matrix as $\mathbf{P}^{(H)} = \mathbf{H}(\mathbf{Q}_S \mathbf{N}^{-1} \mathbf{R} \mathbf{w}_1 \mathbf{v}_1^T + \mathbf{R} \mathbf{w}_1 \mathbf{v}_1^T \mathbf{Q}_T \mathbf{N}^{-1})$ and its dominant
 707 eigenvalue as $\lambda_1^{(H)}$. When the vaccination is targeted to the group i , the relative change in the
 708 dominant eigenvalue $\lambda_1^{(H)}$ is

$$709 \quad \lambda_1^{(H)} w_{i1}^{(H)} = \left(\eta_i R f g (q_i^{(S)} + q_i^{(T)}) \frac{c_i x_i(t) x_i(t)}{a_i s_i(t) n_i} \right) f x_i(t). \quad (\text{Eq.S13})$$

710 We define this expected impact of a single vaccination in group i on the dominant eigenvalue $\lambda_1^{(H)}$
 711 as the importance weight of hospitalization:

$$712 \quad y_i^{(H)} = \eta_i R f g (q_i^{(S)} + q_i^{(T)}) \frac{c_i x_i(t) x_i(t)}{a_i s_i(t) n_i}. \quad (\text{Eq.S14})$$

713 We can interpret this quantity $y_i^{(H)}$ as the expected reduction in the number of new
 714 hospitalizations generated by a typical infected individual in group i after introducing a single unit
 715 of vaccine.

716 1.6 Importance weights for other objectives

717 We can replace the matrix \mathbf{H} (i.e., a diagonal matrix with the elements of infection
 718 hospitalization rates per group i) with different rate matrices for other objectives. In this study, we
 719 also aimed to test an allocation strategy to minimize the number of deaths. Thus, we introduced a
 720 diagonal matrix \mathbf{D} with group-specific infection mortality rate μ_i on the diagonal, and the
 721 importance weight of death $y_i^{(D)}$ can be derived in the same manner as the section 1.5;

$$722 \quad y_i^{(D)} = \mu_i R f g (q_i^{(S)} + q_i^{(T)}) \frac{c_i x_i(t) x_i(t)}{a_i s_i(t) n_i}. \quad (\text{Eq.S15})$$

723 We can interpret this quantity $y_i^{(D)}$ as the expected reduction in the number of new deaths
 724 generated by a typical infected individual in group i after introducing a single unit of vaccine.

725 1.7 Changes in importance weights during the allocation of vaccines

726 Since importance weights are dependent on the number of allocated vaccines, we need to
 727 update them at each allocation step. We denote the changes in importance weights in group i per
 728 single allocation as $\frac{dy_i^{(I)}}{du_i}$, $\frac{dy_i^{(H)}}{du_i}$, and $\frac{dy_i^{(D)}}{du_i}$ for each objective.

732 When vaccines are allocated, the eigenvector \mathbf{w}_1 is perturbed, and its small change $\frac{d\mathbf{w}_1}{du}$ can
 733 be approximated using the Power iteration with the new matrix $\mathbf{K} + \frac{d\mathbf{K}}{dU}$ (see (47), p.331):

734
$$\mathbf{w}_1 + \frac{d\mathbf{w}_1}{du} \sim \left(\mathbf{K} + \frac{d\mathbf{K}}{dU} \right) \mathbf{w}_1$$

735
$$\propto \mathbf{K}\mathbf{w}_1 + \frac{d\mathbf{K}}{dU} \mathbf{w}_1$$

736
$$\propto R\mathbf{w}_1 - \mathbf{Q}_s \mathbf{N}^{-1} R\mathbf{w}_1$$

737 where the sign \propto means “proportional to” and the sign \sim means “approximately proportional to”.
 738 The same derivation has been introduced elsewhere (see section 3.6. of supporting info in (28)). If
 739 the allocation of vaccines is targeted to the group i , this results in the change in the i th element of
 740 the top right eigenvector, such as

741
$$w_{i1} + \frac{dw_{i1}}{du_i} \sim w_{i1} - \frac{q_i^{(S)}}{n_i} w_{i1} \tag{Eq.S16}$$

742 And all other elements remain unchanged (28). We use this equation to quantify the changes in
 743 importance weights after the allocation of a single unit of vaccines. By multiplying both sides of
 744 Eq.S16 by the factor $Rg \left(q_i^{(S)} + q_i^{(T)} \right) \frac{c_i x_i(t)}{a_i s_i(t)} \frac{1}{n_i}$ and using $w_{i1} \approx f x_i(t)$, from Eq.S2 and Eq.S11, we
 745 obtain

746
$$y_i^{(I)} + \frac{dy_i^{(I)}}{du_i} \sim y_i^{(I)} - \frac{q_i^{(S)}}{n_i} y_i^{(I)}.$$

747 Subsequently, we can define the change in the importance weights of hospitalization and death. By
 748 multiplying both sides of Eq.S16 by factors $\eta_i Rg \left(q_i^{(S)} + q_i^{(T)} \right) \frac{c_i x_i(t)}{a_i s_i(t)} \frac{1}{n_i}$ and $\mu_i Rg \left(q_i^{(S)} + \right.$
 749 $\left. q_i^{(T)} \right) \frac{c_i x_i(t)}{a_i s_i(t)} \frac{1}{n_i}$ respectively, from Eq.S2 and Eq.S14-15, we obtain

750
$$y_i^{(H)} + \frac{dy_i^{(H)}}{du_i} \sim y_i^{(H)} - \frac{q_i^{(S)}}{n_i} y_i^{(H)}$$

751 and

752
$$y_i^{(D)} + \frac{dy_i^{(D)}}{du_i} \sim y_i^{(D)} - \frac{q_i^{(S)}}{n_i} y_i^{(D)}.$$

753 The perturbation due to vaccination in group i does not affect other groups.

754

755